Pharmafile Logo
Pharmafocus logo
Advanced Search

Sandoz

Showing 15 posts of 75 posts found.

fda

Biosimilars: Can the US catch up in 2016?

February 12, 2016
Medical Communications, Sales and Marketing Eli Lilly, Enbrel, FDA, Neulasta, Novartis, Pfizer, Sandoz, Zarxio, biosimilars

What are biosimilars? Biosimilars are essentially the biological equivalent of generic drugs to their branded small-molecule counterparts (what Ibuprofen is …

Feature
sandoz_good

Sandoz buys rights to Pfizer biosimilar

February 12, 2016
Medical Communications, Research and Development, Sales and Marketing Pfiizer, Sandoz, biosimilars

Sandoz has announced further expansion to its biosimilars programme with the acquisition of the European rights to Pfizer’s Remicade (infliximab) …

News
sandoz_building

EMA accepts Sandoz Neulasta biosimilar for review

February 11, 2016
Research and Development Amgen, Neulasta, Novartis, Sandoz

Sandoz says the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for its proposed biosimilar to Amgen’s …

News
EMA inside

Sandoz announces biosimilar successes

December 8, 2015
Manufacturing and Production American Society of Hematology, Enbrel, Neulasta, Sandoz, ash, biosimilars, etanercept, pegfilgrastim

Novartis’ biosimilars division Sandoz has announced progress in its biosimilars programme, with its version of Amgen’s Neulasta proving as effective …

News
FDA sign

FDA accepts regulatory submission for Novartis biosimilar

November 18, 2015
Research and Development, Sales and Marketing Neulasta, Novartis, Sandoz, biosimilar, pegfilgrastim

Novartis’ generics unit Sandoz has announced it has had its Biologics License Application (BLA) for a proposed biosimilar to Amgen’s …

News
novartissunlight_copy

Novartis misses Q3 forecast with $390m settlement payment, strong dollar

October 27, 2015
Manufacturing and Production, Sales and Marketing Alcon, Novartis, Sandoz

Novartis reported lower-than anticipated third quarter earnings on Tuesday, hit by the $390 million settlement it has agreed to pay …

News
sandoz_building

FDA accepts Sandoz submission for Amgen biosimilar

October 2, 2015
Medical Communications, Research and Development Amgen, FDA, Novartis, Sandoz, biosimilars

Sandoz, a Novartis company and a global leader in biosimilars, has announced today that the US Food and Drug Administration …

News
BioInject

Sandoz opens €150m manufacturing facility

September 18, 2015
Manufacturing and Production Austria, BioInject, Novartis, Sandoz

Sandoz has opened a €150m state-of-the-art biopharmaceutical manufacturing facility in Schaftenau, Austria.  Known as BioInject will result in the creation …

News
zarxio

Sandoz launches first US biosimilar

September 3, 2015
Manufacturing and Production, Sales and Marketing Amgen, Neupogen, Novartis, Sandoz, Zarxio, biosimilar, biosimilars, filgrastim

Sandoz, the generics arm of the pharma giants Novartis, has become the first company to launch a biosimilar product in …

News
Takeda oncology

Takeda in Velcade patent blow

August 25, 2015
Manufacturing and Production Actavis, Sandoz, Takeda, Velcade, bortezomib, ixazomib

Takeda has lost a court case contesting the patent for its blockbuster multiple myeloma drug Velcade, in a decision that …

News
Novartis

Sandoz and pharma division boost Novartis sales

July 21, 2015
Sales and Marketing Alcon, Novartis, Sandoz, financial performance, financial results, income, profits, sales

Sales at Novartis reached $12.7 billion in the second quarter of 2015, while its operating income was $2.3 billion, the …

News

Novartis and Pfizer to close factories in India

July 21, 2015
Manufacturing and Production India, Novartis, Pfizer, Sandoz, manufacturing

Two big pharma firms have announced they will close manufacturing facilities in India as they seek to restructures their global …

News
sandoz image

Novartis invests further into Poland

May 11, 2015
Manufacturing and Production, Sales and Marketing Novartis, Poland, Sandoz, manufacturing, packaging

Sandoz the generics division of Novartis has opened a large packaging centre in Stryków in Poland. Valued at 171 million …

News
Copaxone image

FDA approves generic Copaxone for multiple sclerosis

April 17, 2015
Sales and Marketing FDA, Sandoz, Teva, glatiramer acetate injection, glatopa

The FDA has signed-off on the first generic version of Copaxone to treat people with relapsing forms of multiple sclerosis …

News
Novartis image

Novartis secures first US biosimilar product

March 6, 2015
Research and Development, Sales and Marketing Amgen, Cancer, FDA, Neupogen, Novartis, Sandoz, Zarxio, biosimilar, filgrastim-sndz

Novartis’ generic arm Sandoz has won the race to become the first company to market a biosimilar in the US …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025